Abstract
Anti-phospholipid antibodies (aPLs) are present in a wide range of infectious and autoimmune diseases. aPLs, in particular anti-cardiolipin antibodies (aCL) and lupus anticoagulants (LA), are of considerable clinical importance because of the close association with predominant clinical features of venous, arterial thrombosis, and pregnancy morbidity. The term "antiphospholipid syndrome (APS)" has been used to define this set of pathologic features. Numerous studies have elucidated the specificity of anti-phospholipid antibodies (aPLs). It is clear that the nomenclature of aPLs is a misnomer and that these autoantibodies react with phospholipid-binding plasma proteins (cofactors), such as β2-glycoprotein, prothrombin, annexin V, high-molecular-weight kininogen, protein S, and protein C. Many varieties of pathophysiologic mechanisms have been explored in order to understand the wide spectrum of antigenic specificities of aPLs. Numerous observations are reviewed in this discussion concerning putative mechanisms related to anti-β2-GPI antibodies or other aPLs predisposing to thrombosis and to atherosclerosis.
| Original language | English |
|---|---|
| Title of host publication | Systemic Lupus Erythematosus: Fourth Edition |
| Publisher | Elsevier Inc. |
| Pages | 1081-1105 |
| Number of pages | 25 |
| ISBN (Print) | 9780124339019 |
| DOIs | |
| Publication status | Published - May 2004 |
Fingerprint
ASJC Scopus subject areas
- Immunology and Microbiology(all)
Cite this
Immunology of anti-phospholipid antibodies and cofactors. / Atsumi, Tatsuya; Matsuura, Eiji; Koike, Takao.
Systemic Lupus Erythematosus: Fourth Edition. Elsevier Inc., 2004. p. 1081-1105.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Immunology of anti-phospholipid antibodies and cofactors
AU - Atsumi, Tatsuya
AU - Matsuura, Eiji
AU - Koike, Takao
PY - 2004/5
Y1 - 2004/5
N2 - Anti-phospholipid antibodies (aPLs) are present in a wide range of infectious and autoimmune diseases. aPLs, in particular anti-cardiolipin antibodies (aCL) and lupus anticoagulants (LA), are of considerable clinical importance because of the close association with predominant clinical features of venous, arterial thrombosis, and pregnancy morbidity. The term "antiphospholipid syndrome (APS)" has been used to define this set of pathologic features. Numerous studies have elucidated the specificity of anti-phospholipid antibodies (aPLs). It is clear that the nomenclature of aPLs is a misnomer and that these autoantibodies react with phospholipid-binding plasma proteins (cofactors), such as β2-glycoprotein, prothrombin, annexin V, high-molecular-weight kininogen, protein S, and protein C. Many varieties of pathophysiologic mechanisms have been explored in order to understand the wide spectrum of antigenic specificities of aPLs. Numerous observations are reviewed in this discussion concerning putative mechanisms related to anti-β2-GPI antibodies or other aPLs predisposing to thrombosis and to atherosclerosis.
AB - Anti-phospholipid antibodies (aPLs) are present in a wide range of infectious and autoimmune diseases. aPLs, in particular anti-cardiolipin antibodies (aCL) and lupus anticoagulants (LA), are of considerable clinical importance because of the close association with predominant clinical features of venous, arterial thrombosis, and pregnancy morbidity. The term "antiphospholipid syndrome (APS)" has been used to define this set of pathologic features. Numerous studies have elucidated the specificity of anti-phospholipid antibodies (aPLs). It is clear that the nomenclature of aPLs is a misnomer and that these autoantibodies react with phospholipid-binding plasma proteins (cofactors), such as β2-glycoprotein, prothrombin, annexin V, high-molecular-weight kininogen, protein S, and protein C. Many varieties of pathophysiologic mechanisms have been explored in order to understand the wide spectrum of antigenic specificities of aPLs. Numerous observations are reviewed in this discussion concerning putative mechanisms related to anti-β2-GPI antibodies or other aPLs predisposing to thrombosis and to atherosclerosis.
UR - http://www.scopus.com/inward/record.url?scp=8344236700&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=8344236700&partnerID=8YFLogxK
U2 - 10.1016/B978-012433901-9/50042-9
DO - 10.1016/B978-012433901-9/50042-9
M3 - Chapter
AN - SCOPUS:8344236700
SN - 9780124339019
SP - 1081
EP - 1105
BT - Systemic Lupus Erythematosus: Fourth Edition
PB - Elsevier Inc.
ER -